
James Mittra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2483649/publications.pdf Version: 2024-02-01



IAMES MITTDA

#	Article	IF	CITATIONS
1	Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms. Technology Analysis and Strategic Management, 2007, 19, 279-301.	3.5	54
2	Twenty-first century bioeconomy: Global challenges of biological knowledge for health and agriculture. Science and Public Policy, 2013, 40, 17-24.	2.4	32
3	Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem. Clinical Therapeutics, 2018, 40, 1084-1094.	2.5	32
4	Analysing stratified medicine business models and value systems: innovation-regulation interactions. New Biotechnology, 2012, 29, 709-719.	4.4	21
5	The New Health Bioeconomy. , 2016, , .		17
6	Unpacking the Concept of Bioeconomy: Problems of Definition, Measurement, and Value. Science and Technology Studies, 2020, 33, 2-21.	0.7	16
7	From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. Trends in Biotechnology, 2011, 29, 105-109.	9.3	15
8	Repairing the â€ [~] Broken Middle' of the Health Innovation Pathway. Science and Technology Studies, 2013, 26, 103-123.	0.7	13
9	Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms. International Journal of Biotechnology, 2008, 10, 416.	1.2	12
10	Predictive Genetic Information and Access to Life Assurance: The Poverty of â€~Genetic Exceptionalism'. BioSocieties, 2007, 2, 349-373.	1.3	10
11	â€~Genetic exceptionalism' and precautionary politics: regulating for uncertainty in Britain's genetics and insurance policy process. Science and Public Policy, 2006, 33, 585-600.	2.4	9
12	The Socio-Political Economy of Pharmaceutical Mergers: A Case Study of Sanofi and Aventis. Technology Analysis and Strategic Management, 2006, 18, 473-496.	3.5	7
13	Understanding the emergence and evolution of new business models in the UK regenerative medicine sector. Technology Analysis and Strategic Management, 2021, 33, 320-333.	3.5	6
14	Evolution of the Life Science Industries. Technology Analysis and Strategic Management, 2007, 19, 251-255.	3.5	5
15	Conceptualising and practising multiple knowledge interactions in the life sciences. Technological Forecasting and Social Change, 2017, 116, 308-315.	11.6	5
16	Political influences on biotechnology-based innovation for European agriculture: risk-assessment and risk management. Technology Analysis and Strategic Management, 2021, 33, 271-282.	3.5	5
17	Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine. Therapeutic Innovation and Regulatory Science, 2016, 50, 724-733.	1.6	4
18	Re-Imagining Healthcare and Medical Research Systems in Post-Devolution Scotland. Sociological Research Online, 2019, 24, 55-72.	1.1	3

JAMES MITTRA

#	Article	IF	CITATIONS
19	Pharmaceutical industries: do they prefer treatment to cure?. Biochemist, 2005, 27, 32-34.	0.5	3
20	Regenerative medicine as a disruptive technology: implications for manufacturing & clinical adoption. Cell & Gene Therapy Insights, 2019, 5, 1287-1303.	0.1	3
21	Marginalising â€~eugenic anxiety' through a rhetoric of â€~liberal choice': a critique of the House of Commons Select Committee Report on reproductive technologies. New Genetics and Society, 2007, 26, 159-179.	1.2	2
22	Regulatory and market influences on innovation pathways for the development of new antimicrobial drugs. Technology Analysis and Strategic Management, 2021, 33, 283-295.	3.5	2
23	Organizational Transformations and the Value of Interdisciplinarity. , 2016, , 87-119.		0